FUJIFILM Holdings Corporation
4901・Prime Market・Chemicals
Business
FUJIFILM Holdings traces its origins to a photographic film manufacturer founded in 1934, and now comprises four segments: Healthcare (medical systems, Bio CDMO, life sciences), Electronics (semiconductor materials, display materials), Business Innovation (multifunction printers, solutions, commercial printing), and Imaging (instax, digital cameras). Of consolidated net sales of ¥3,356,969 million, overseas sales account for approximately 65%, or ¥2,188,287 million, with the company operating globally through 258 subsidiaries and 27 affiliated companies. Major customers span a wide range including major pharmaceutical companies, semiconductor foundries, corporate offices, and general consumers, reflecting a diversified portfolio with low dependence on any specific market.
Business Model
The company horizontally deploys functional materials, precision optics, and image processing technologies cultivated through photographic film development, offering high-value-added products across each segment. Stable earnings are underpinned by: in Healthcare, recurring revenue from maintenance services and consumables plus long-term Bio CDMO manufacturing agreements (with Johnson & Johnson, Regeneron, etc.); in Electronics, ongoing supply of advanced semiconductor materials; in Business Innovation, SaaS-based cloud services; and in Imaging, steady demand for instax (Instant Photo System) film consumables. The structure concentrates capital expenditure (¥506,945 million in FY2026 (ending March 2026)) on growth areas, funded by operating cash flow (¥410,555 million), to sustain a continuous cycle of growth investment.
Company Strengths
The company has redeployed functional molecular design, organic synthesis, and formulation technologies cultivated in silver halide photography research into semiconductor photoresists, CMP slurries, biological culture media, medical image processing, and other fields. It holds the world's top share in NTI developer and copper interconnect CMP slurry, and in April 2026 became the first in the world to develop a fluorine-free ArF resist, demonstrating an accumulation of technology that is difficult for competitors to replicate in a short period.
A new plant in North Carolina, USA (equipped with eight 20,000-liter culture tanks) began operations in FY2025, and the company has already concluded long-term manufacturing agreements with Johnson & Johnson group company Janssen Supply Group, Regeneron (total contract value exceeding $3 billion over 10 years), and argenx. In the UK, a drug substance manufacturing building involving an investment of approximately £400 million opened in February 2026, establishing a global four-site operational structure.
The instax series surpassed cumulative sales of 100 million units, and the Imaging segment's operating margin for FY2026 (ending March 2026) reached 25.5% (operating income of ¥160,003 million), the highest level among all segments. The company continues to launch new products such as the instax mini Evo Cinema and mini LiPlay+, and announced an expansion of film production facilities in December 2025. The structure in which stable demand for consumables (film) generates recurring revenue underpins the high profit margin.
ENVALITH's Perspective
Performance Trend
Revenue grew 33% over four years, from ¥2,525,773 million in FY2022 (ended March 2022) to ¥3,356,969 million in FY2026 (ending March 2026), marking a new record high for four consecutive fiscal years. Operating income also expanded from ¥273,079 million in FY2023 (ended March 2023) to ¥350,210 million in FY2026 (ending March 2026), with the operating margin improving 0.1 points year on year to 10.4%. As an external factor, the yen depreciated against the euro from ¥164 in the previous fiscal year to ¥175, contributing to an increase in the yen-translated value of overseas sales (65.2% of total sales). On the other hand, aggressive capital investment in Bio CDMO and Semiconductor Materials (Cmp Slurry, Photoresist, NTI Developer, Process Chemicals) (¥581,976 million on a consolidated basis) caused free cash flow to turn negative. For FY2027 (ending March 2027), the company forecasts revenue of ¥3,470,000 million (up 3.4% year on year) and operating income of ¥365,000 million (up 4.2% year on year), expecting the trend of increasing revenue and profit to continue.
Growth Strategy
Aim to achieve VISION2030 through accelerated growth in Healthcare and Electronics and structural reform of Business Innovation
Began operation of eight 20,000-liter animal cell culture tanks at the North Carolina site in the U.S., and concluded long-term manufacturing agreements with Johnson & Johnson, Regeneron, and others. Opened an antibody drug substance manufacturing building at the UK site. Moving forward with an earlier start-up timeline for the second-phase investment to capture robust growth in demand for antibody drug contract manufacturing.
Capturing AI semiconductor demand with a product lineup including advanced photoresists, CMP slurry, NTI developer, and liquid-type polyimide, achieving an operating margin of 22.1% in the Electronics segment. Laying groundwork for next-generation markets, including completion of a ¥5.0 billion investment in Rapidus and acquisition of land for a manufacturing site in India.
Expanding the user base with new products such as the instax mini Evo Cinema and instax mini LiPlay+, and responding to expanding global demand by increasing instax film production capacity. Extending the Imaging segment's growth areas through full-scale entry into the video production market with the GFX ETERNA 55.
Expanding the recurring business through the European and North American rollout of the core systems business centered on Microsoft Dynamics 365 following the acquisition of ETG Global, AI feature enhancement for FUJIFILM IWpro, and development of a feature utilizing Microsoft Copilot for Seven-Eleven's multi-copy machines (planned for launch during FY2026, ending March 2026).
Last updated: July 19, 2026